达格列净联合二甲双胍、阿卡波糖治疗早期糖尿病肾病的临床效果  

Clinical Effect of Dapagliflozin Combined with Metformin and Acarbose in Treatment of Early-Stage Diabetic Nephropathy

作　　者：缪静 Miao Jing(Hemodialysis Center,Beijing Daxing Jiugong Hospital,Beijing 100076,China)

机构地区：[1]北京市大兴区旧宫医院血液透析中心,北京100076

出　　处：《中国社区医师》2025年第3期15-17,共3页Chinese Community Doctors

摘　　要：目的:探讨达格列净联合二甲双胍、阿卡波糖治疗早期糖尿病肾病的临床效果。方法:将2022年1月—2023年12月北京市大兴区旧宫医院收治的早期糖尿病肾病患者86例作为研究对象,以随机数字表法分为对照组(采用二甲双胍、阿卡波糖治疗)和研究组(采用达格列净联合二甲双胍、阿卡波糖治疗),各43例。对比两组患者血糖、肾功能、药物不良反应。结果:治疗前,两组空腹血糖、餐后2 h血糖、糖化血红蛋白水平比较,差异无统计学意义(P>0.05);治疗后,两组血糖指标均明显降低,且研究组空腹血糖、餐后2 h血糖、糖化血红蛋白水平较对照组低(P<0.05)。治疗前,两组尿素氮、血肌酐、胱抑素C水平,肾小球滤过率、尿白蛋白/肌酐比较,无统计学差异(P>0.05);治疗后,两组尿素氮、血肌酐、胱抑素C水平,尿白蛋白/肌酐降低,肾小球滤过率提高,且研究组改善幅度大于对照组(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P=0.557)。结论:达格列净联合二甲双胍、阿卡波糖治疗早期糖尿病肾病的临床效果显著,能有效控制患者血糖水平,改善肾功能,且用药安全性较高。Objective:To explore the clinical effect of dapagliflozin combined with metformin and acarbose in treatment of earlystage diabetic nephropathy.Methods:A total of 86 patients with early-stage diabetic nephropathy admitted to Beijing Daxing Jiugong Hospital from January 2022 to December 2023 were selected as the study subjects.They were divided into the control group(treated with metformin and acarbose)and the study group(treated with dapagliflozin combined with metformin and acarbose)by random number table method,with 43 cases in each group.Blood glucose,renal function and adverse drug reactions were compared between the two groups.Results:Before treatment,there was no statistically significant difference in the levels of fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin between the two groups(P>0.05).After treatment,blood glucose indicators in two groups significantly decreased,and the levels of fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in the study group were lower than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in the levels of urea nitrogen,serum creatinine and cystatin C,glomerular filtration rate and urine albumin/creatinine between the two groups(P>0.05).After treatment,the levels of urea nitrogen,serum creatinine and cystatin C,as well as urine albumin/creatinine decreased and glomerular filtration rate increased in the two groups,and the improvement in the study group was greater than that in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P=0.557).Conclusion:Dapagliflozin combined with metformin and acarbose has significant clinical effect in the treatment of early-stage diabetic nephropathy,and can effectively control blood glucose levels and improve renal function,with high medication safety.

关 键 词：达格列净 糖尿病肾病 二甲双胍 阿卡波糖 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]